Join the club for FREE to access the whole archive and other member benefits.

AgomAb raises €62M in Series B round to advance regenerative medicine

Funds to bring the experimental drug to trials; symbolizes booming regenerative niche

16-Mar-2021

Key points from article :

AgomAb Therapeutics announced €62M in series B funding round last week.

Harnessing antibodies that kickstart healing and tackle metabolic, inflammatory, and fibrotic conditions.

Funding to advance into clinical trials AgomAb’s flagship monoclonal antibody, which is inspired by the minuscule antibodies of llamas.

Mimics the action of the hepatocyte growth factor (HGF) protein.

Developing monoclonal antibodies using antibody technology to provide both stability and ability to target specific human tissues.

Global market for regenerative therapies is expected to triple between 2019 and 2025.

AgomAb’s hefty round is widely seen as a positive signal for other companies in regenerative medicine.

Ilya Pharma plans to kick off phase II testing its lead candidate in the next few months.

Novadip received a nod from the US FDA earlier this month to begin human trials of its cell therapy targeting bone regeneration.

Elastrin Therapeutics seeks to reverse cardiovascular disease using nanotechnology.

Mentioned in this article:

Click on resource name for more details.

AgomAb Therapeutics

Leading company in developing antibody therapies for regenerative medicine

Elastrin Therapeutics

South Carolina-based biotech developing novel therapies

Ilya Pharma

Clinical stage biopharmaceutical company developing immunotherapies to treat wounds in skin and mucosa

Novadip

Novel stem cell therapies for regenerative medicine using its unique 3M3 tissue regeneration platform

Topics mentioned on this page:
Investments, Regenerative Medicine